RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arbutus Biopharma Stock

Arbutus Biopharma ROCE 2024

Arbutus Biopharma ROCE

-0.74

Ticker

ABUS

ISIN

CA03879J1003

WKN

A14XMD

In 2024, Arbutus Biopharma's return on capital employed (ROCE) was -0.74, a 53.96% increase from the -0.48 ROCE in the previous year.

Arbutus Biopharma Aktienanalyse

What does Arbutus Biopharma do?

Arbutus Biopharma Corp is a biopharmaceutical company that focuses on developing novel treatment methods for viral diseases. The company, based in Vancouver, Canada, was founded in 2008. The history of Arbutus Biopharma Corp began with the merger of Tekmira Pharmaceuticals and OnCore Biopharma in 2015. The merger strengthened the company and expanded its ability to develop innovative therapies for Hepatitis B and Hepatitis D viruses. The ability to bring the companies together also demonstrates the team, consisting of experienced experts from various areas such as the healthcare industry, biotech engineering, finance, and pharmacy. The business model of Arbutus Biopharma Corp is to explore, develop, and market novel treatment methods for viral diseases. Marketing is done through partnerships with other companies that commercialize the products. The company relies on research and development agreements to enter into synergistic partnerships that work on the same wavelength. One of the key divisions of Arbutus Biopharma Corp is the development of RNA interference (RNAi) therapies. These therapies aim to suppress the genetic information that leads to viral replication in cells. The company has an extensive patent portfolio and comprehensive expertise in the field of RNAi therapy. RNAi therapy opens up a new paradigm in the treatment of viral diseases. The company has also developed products such as the HBV Antisense platform. The HBV Antisense platform utilizes a special type of RNA-based medication to suppress the production of proteins necessary for the replication of the Hepatitis B virus. This strategy allows for the reduction of viral RNA replication and strengthens the immune system to fight against or prevent viral infections. The company also pursues an advanced pipeline in the preclinical phase to develop a melanocortin receptor antagonist and an artificial antibody against Hepatitis B. Another business area of Arbutus Biopharma Corp is collaboration with other companies to outsource innovative technologies and products. One of the key partnerships is with Roivant Sciences Ltd. Roivant Sciences Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative therapy approaches. The partnership between Arbutus Biopharma Corp and Roivant Sciences Ltd creates a win-win situation for both, bringing about synergies and enabling capital and risk sharing. In summary, Arbutus Biopharma Corp is a biopharmaceutical company that focuses on the development of novel therapies for viral diseases. The company has a broad portfolio of innovative products in the field of RNAi therapy and HBV Antisense platform. Arbutus Biopharma Corp strives to achieve advancements in the development of therapies for viral diseases through partnerships and alliances with other companies. Arbutus Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Arbutus Biopharma's Return on Capital Employed (ROCE)

Arbutus Biopharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Arbutus Biopharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Arbutus Biopharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Arbutus Biopharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Arbutus Biopharma stock

What is the ROCE (Return on Capital Employed) of Arbutus Biopharma this year?

The ROCE of Arbutus Biopharma is -0.74 undefined this year.

How has the ROCE (Return on Capital Employed) of Arbutus Biopharma developed compared to the previous year?

The ROCE of Arbutus Biopharma has increased by 53.96% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Arbutus Biopharma?

A high Return on Capital Employed (ROCE) indicates that Arbutus Biopharma has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Arbutus Biopharma?

A low ROCE (Return on Capital Employed) can indicate that Arbutus Biopharma has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Arbutus Biopharma impact the company?

An increase in the ROCE of Arbutus Biopharma can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Arbutus Biopharma affect the company?

A decrease in ROCE of Arbutus Biopharma can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Arbutus Biopharma?

Some factors that can affect Arbutus Biopharma's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Arbutus Biopharma so important for investors?

The ROCE of Arbutus Biopharma is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Arbutus Biopharma take to improve the ROCE?

To improve the ROCE, Arbutus Biopharma can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Arbutus Biopharma pay?

Over the past 12 months, Arbutus Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arbutus Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Arbutus Biopharma?

The current dividend yield of Arbutus Biopharma is .

When does Arbutus Biopharma pay dividends?

Arbutus Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arbutus Biopharma?

Arbutus Biopharma paid dividends every year for the past 0 years.

What is the dividend of Arbutus Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arbutus Biopharma located?

Arbutus Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arbutus Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arbutus Biopharma from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Arbutus Biopharma pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Arbutus Biopharma in the year 2023?

In the year 2023, Arbutus Biopharma distributed 0 USD as dividends.

In which currency does Arbutus Biopharma pay out the dividend?

The dividends of Arbutus Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Arbutus Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Arbutus Biopharma

Our stock analysis for Arbutus Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arbutus Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.